Table 5.
Sensitivity/specificity for TRIM21, NY-ESO-1, TP53, and PAX8, Validation II
| Late stage HGSOC (n = 45) | Early stage HGSOC (n = 5) | Late and early stage HGSOC (n = 50) | Benign (n = 50) | Healthy (n = 50) | Benign and healthy (n = 100) | |
|---|---|---|---|---|---|---|
| Positive threshold = 2 | ||||||
| Antigen | Sensitivity | Sensitivity | Sensitivity | Specificity | Specificity | Specificity |
| TRIM21 | 0.38 | 0.20 | 0.36 | 0.90 | 0.96 | 0.93 |
| TP53 | 0.16 | 0.00 | 0.14 | 0.96 | 0.96 | 0.96 |
| NYESO1 | 0.20 | 0.00 | 0.18 | 0.94 | 1.00 | 0.97 |
| PAX8 | 0.09 | 0.00 | 0.08 | 0.98 | 0.96 | 0.97 |
| TRIM21, TP53, NYESO1 | 0.51 | 0.20 | 0.48 | 0.80 | 0.92 | 0.86 |
| TRIM21, TP53, NYESO1, PAX8 | 0.53 | 0.20 | 0.50 | 0.80 | 0.88 | 0.84 |
| Positive threshold = 3 | ||||||
| Antigen | Sensitivity | Sensitivity | Sensitivity | Specificity | Specificity | Specificity |
| TRIM21 | 0.24 | 0.20 | 0.24 | 0.98 | 1.00 | 0.99 |
| TP53 | 0.16 | 0.00 | 0.14 | 1.00 | 0.98 | 0.99 |
| NYESO1 | 0.20 | 0.00 | 0.18 | 0.98 | 1.00 | 0.99 |
| PAX8 | 0.04 | 0.00 | 0.04 | 0.98 | 1.00 | 0.99 |
| TRIM21, TP53, NYESO1 | 0.49 | 0.20 | 0.46 | 0.96 | 0.98 | 0.97 |
| TRIM21, TP53, NYESO1, PAX8 | 0.49 | 0.20 | 0.46 | 0.94 | 0.98 | 0.96 |
Sensitivity and specificity for TRIM21, NY-ESO-1, TP53, and PAX8. Threshold (2) = Mean + 2 (StdDev) for healthy controls, threshold (3) = Mean + 3 (StdDev) for healthy controls.